Recently, Le et al. 33 reported that colorectal and other cancers with germline or somatic loss of DNA mismatch repair (MMR) genes have a significantly higher response rate and 12-week clinical benefit rate to pembrolizumab than MMR-proficient colorectal tumors. Here, MRC1 is linked to cancer.